- Research article
- Open Access
Abnormalities of cell packing density and dendritic complexity in the MeCP2 A140V mouse model of Rett syndrome/X-linked mental retardation
© Jentarra et al; licensee BioMed Central Ltd. 2010
Received: 14 October 2009
Accepted: 17 February 2010
Published: 17 February 2010
Rett syndrome (RTT), a common cause of mental retardation in girls, is associated with mutations in the MECP2 gene. Most human cases of MECP2 mutation in girls result in classical or variant forms of RTT. When these same mutations occur in males, they often present as severe neonatal encephalopathy. However, some MECP2 mutations can also lead to diseases characterized as mental retardation syndromes, particularly in boys. One of these mutations, A140V, is a common, recurring missense mutation accounting for about 0.6% of all MeCP2 mutations and ranking 21st by frequency. It has been described in familial X-linked mental retardation (XLMR), PPM- X syndrome (Parkinsonism, Pyramidal signs, Macroorchidism, X-linked mental retardation) and in other neuropsychiatric syndromes. Interestingly, this mutation has been reported to preserve the methyl-CpG binding function of the MeCP2 protein while compromising its ability to bind to the mental retardation associated protein ATRX.
We report the construction and initial characterization of a mouse model expressing the A140V MeCP2 mutation. These initial descriptive studies in male hemizygous mice have revealed brain abnormalities seen in both RTT and mental retardation. The abnormalities found include increases in cell packing density in the brain and a significant reduction in the complexity of neuronal dendritic branching. In contrast to some MeCP2 mutation mouse models, the A140V mouse has an apparently normal lifespan and normal weight gain patterns with no obvious seizures, tremors, breathing difficulties or kyphosis.
We have identified various neurological abnormalities in this mouse model of Rett syndrome/X-linked mental retardation which may help to elucidate the manner in which MECP2 mutations cause neuronal changes resulting in mental retardation without the confounding effects of seizures, chronic hypoventilation, or other Rett syndrome associated symptoms.
Rett syndrome (RTT; OMIM #312750) is an X-linked dominant neurological disorder affecting predominantly females [1, 2] and has an estimated prevalence of 1 in 10,000-15,000 females . In patients with RTT, symptoms are generally recognized around 6 to 18 months of age following an apparently normal period of early development. Regression of previously acquired skills and deceleration of head growth are key features of the disease in conjunction with stereotypic hand movements. Ultimately, affected individuals frequently display cognitive, social, and language impairments as well as a variety of serious motor and breathing abnormalities, seizures, microcephaly, gastrointestinal dysfunction, scoliosis, kyphosis, and rigidity [2–4]. Pathological studies of human RTT cases have shown a reduction in brain size, and an increase in cell packing density [5, 6]. These studies have also noted a significant reduction in the dendritic branching of neurons in specific layers of the frontal, motor, temporal and limbic cortex [6–9].
Most cases of RTT are caused by point mutations, insertions, duplications, or deletions in the MECP2 (methyl-CpG binding protein 2) gene [1, 4, 10]. Over 300 distinct MECP2 mutations have been described and certain mutations occur with high frequency (T158M, R168X, R255X, R270X, R294X, R306C, R133C, and R106W) (IRSA MeCP2 Variation Database, http://mecp2.chw.edu.au/mecp2/). At least two important functional domains within the MeCP2 protein have been identified. The first is a methyl-CpG binding domain (MBD) which binds specifically to methylated CpG- dinucleotides and the second is a transcriptional repressor domain (TRD), which interacts with a transcriptional repressor complex [11, 12]. While widely described in the past as a transcriptional repressor, a recent report indicates that MeCP2 may also be a transcriptional activator, and may actually function more often as an activator than a repressor of transcription . It is also believed to participate in recruiting chromatin remodeling and co-repressor proteins [11, 12], and . MeCP2 acts to modulate the transcription of many genes, one of which, BDNF [13, 15, 16], is particularly relevant to diseases causing mental retardation as it is heavily involved in synaptic plasticity  and influences disease progression in Mecp2 mutant mice .
In addition to the classic or variant RTT phenotypes in females, MECP2 gene mutation has also been described in males [19–21], sometimes causing a severe and fatal early onset encephalopathy . One specific mutation of MeCP2, A140V, does not result in a severe phenotype or in early lethality. While not resulting in classical RTT features, this mutation has been reported to cause X-linked mental retardation (XLMR) and neuropsychiatric syndromes as well as PPM-X syndrome (OMIM #300055; Parkinsonism, Pyramidal signs, Macroorchidism, X-linked mental retardation) [23–26]. The A140V mutation is a recurring mutation within the MBD of MeCP2 accounting for about 0.6% of all reported MeCP2 mutations (IRSA MeCP2 Variation Database, http://mecp2.chw.edu.au/mecp2/). This mutation was first reported in a female with mild mental retardation, her daughter with mild mental retardation, and her four sons with severe mental retardation . In a cohort of mentally retarded patients negative for expansion of the CGG repeat at the FMR1 locus, Couvert et al found two sporadic cases of A140V mutation . A three-generation family with five affected males (MRX 79) was shown to carry the A140V mutation . The A140V mutation has also been reported in a young boy with language disorder and schizophrenia . In addition to the previously listed symptoms, dysarthric speech, mild dysmorphic features, spasticity, gait abnormalities, mild microcephaly, trophic changes of the legs, distal atrophy in the limbs, kyphoscoliosis, ankle clonus, and abnormal deep tendon reflexes are also symptoms associated with this mutation . Thus, the A140V MeCP2 mutation is an important cause of XLMR and developmental disorders and is somewhat distinct clinically from classic RTT.
It has been predicted based on structural data that the A140V mutation, located in the α1 helix of the MBD, could potentially affect the structure of the MeCP2 MBD and therefore the methyl-CpG DNA binding function. Ohki, et al.  speculate that due to its bulky side chain, the substituted valine may cause reduced DNA binding affinity and Orrico, et al.,  using secondary structure prediction programs, proposed that the A140V mutation shortens the α1 helix by half, potentially resulting in an alteration of function. Although many MECP2 gene mutations do affect the methyl-CpG DNA binding function of the MeCP2 protein, the A140V mutation has been reported not to, despite predictions based on its location within that functional domain . Indeed, MeCP2 A140V protein localizes to heterochromatic foci, containing abundant methyl- CpG sites, as efficiently as wild type (WT) MeCP2. In addition, DNA binding assays in cultured cells have demonstrated that the A140V mutation does not affect binding to methylated DNA [29, 30]. Nevertheless, another interesting property of MeCP2 A140V protein was discovered in studies of transcriptional activity in transfected cells. MeCP2 A140V repressed transcriptional activity from methylated promoters at levels comparable to WT and from unmethylated promoters at a level approximately 40% higher than WT MeCP2 . This raises the possibility that higher repressive activity by MeCP2 A140V may affect the normal expression of unmethylated genes.
The A140V mutation is also reported to directly affect the ability of MeCP2 to bind to the ATRX protein , a helicase/ATPase believed to be involved in chromatin remodeling . Alpha-thalassemia X-linked mental retardation syndrome (ATRX; OMIM #301040) is caused by mutation of the ATRX gene. In addition to the hematologic abnormality alpha-thalassemia, ATRX gene mutations also result in mental retardation, microcephaly, dysmorphic features, genital and renal abnormalities, growth deficiency, seizures, spasticity, gastrointestinal dysfunction, and kyphoscoliosis and other skeletal abnormalities [31–34]. Many of the symptoms of ATRX overlap those seen in patients with a classic RTT mutation of the MECP2 gene. There are also clear differences, the presence of dysmorphic features in ATRX mutations for example. Interestingly, the A140V mutation reproduces symptoms of both conditions while still being somewhat distinct from each of them. This may provide a glimpse into the mechanism underlying each of these conditions. Currently there are no complete ATRX knock out mouse models due likely to the described embryonic lethality in males . Tissue specific conditional inactivation of ATRX results in enhanced cell death during corticogenesis with early lethality (forebrain specific inactivation)  and interneuron defects in the retina (retina specific inactivation) .
A variety of mouse models of RTT have been previously developed and tested. One of the first Mecp2 mutant mouse models generated lacked exons 3 and 4. This model demonstrated that MeCP2-null animals were viable and did not have a specific initial phenotype. Between the ages of 3 and 8 weeks these animals (null males) developed abnormalities of gait and breathing, ultimately leading to early death at around 2 months of age . A second MeCP2-null mouse was generated by deletion of Exon 3. Male mice appeared healthy for the first few weeks of age but developed abnormal movements, motor control, and breathing by 5 weeks of age with death occurring around 10 weeks. Female mice in this study exhibited similar symptoms but with a time course delayed by months .
Shahbazian et al.  generated mice with truncation of the C-terminal third of the coding region (308/y mouse) by introducing a stop codon following amino acid 308, which is located at the C terminal end of the transcriptional repressor domain. Male mutant mice survived to at least 1 year of age and developed a variety of symptoms including tremor, myoclonic seizures, kyphosis and stereotyped forelimb movements. The motor performance of these mice declined with age. Histological studies of the brain were normal and fear conditioning and spatial learning were normal, however, the mice did display enhanced anxiety and an abnormal corticosterone stress response . Recently, a knock-in model of RTT (R168X) was generated, reproducing a common non-sense mutation of MeCP2 found in human cases. As with other RTT model mice, male R168X mice die early at around 12 weeks of age, but display symptoms suggestive of RTT such as breathing irregularities, hypoactivity, and hind limb atrophy and clasping. Female heterozygous mice show similar symptoms but not until around 6 months of age . As reported in pathological studies of human RTT brain tissues [5, 6], abnormalities of brain size [39, 43] and cell packing density have been observed in mouse models of RTT [39, 44, 45]. Abnormalities of dendrite branching have also been reported in some Rett syndrome mouse models [44, 45]. Much of the testing in mouse models has been done using hemizygous males to avoid the phenotype variability resulting from random X inactivation in females, which is considered to influence phenotype in human RTT patients. We have performed our initial tests in males for this reason and because A140V is more commonly recognized in longer surviving male patients.
The pathogenesis of the neurological phenotype in RTT remains unclear, and continued study of mouse models will improve our understanding. The various mouse models recapitulate the symptoms of RTT in many ways but are often distinct from each other. Although much has been learned about RTT through the study of existing mouse models, the A140V model we have created is unique. It reproduces a recurring missense mutation seen in humans and, in males, results in an XLMR phenotype (rather than classical RTT). In addition, due to the long life span of mutant male mice, developmental studies can be performed. We expect that by a careful analysis of the A140V mouse, we will better understand the important roles that MeCP2 plays in the pathogenesis of developmental brain disorders that result in mental retardation. Here we describe the construction and initial characterization of brain abnormalities in the MeCP2 A140V mutant mouse model of RTT/XLMR. In addition to being a model for these two diseases, the A140V mutant mouse permits the study of a novel mechanism by which MeCP2 mutation might affect neural development; its interaction with the ATRX chromatin remodeling protein.
Generation of the MeCP2 A140V mutant mouse
Mutant Mecp2 mRNA is expressed in brain tissue
MeCP2 protein is expressed in the brain of A140V mutant animals
As this is not a knock-out or truncating model, it was expected that the full length MeCP2 protein would be present in the brains of hemizygous male mice. Immunostaining in brain slices using an anti-MeCP2 antibody directed against the C-terminus of the protein demonstrated the presence of the MeCP2 protein in the brain tissue of hemizygous mice as well as wild type control mice (Figure 2B). A peptide blocking assay confirmed the specificity of the antibody (data not shown). The mutation does not appear to have affected the nuclear or brain regional distribution of MeCP2 protein.
Mecp2 mRNA levels in wild-type and A140V mouse cerebellum by qRT-PCR
There are no obvious phenotypic abnormalities of the A140V mice
Increase in cell packing density in mutant animals
Abnormal dendritic branching in mutant cortical neurons
The A140V mouse model was constructed in order to more closely examine the mental retardation associated with RTT. This was expected to be a mental retardation model in mice due to the effects of this mutation in human male patients. Male patients with the A140V mutation survive into adulthood, indicating that this mutation is less likely to compromise functions essential for life. However, significant mental retardation is common in males carrying this mutation while carrier females show mild or no symptoms [23–26]. The A140V mutation is predicted to be non-truncating and this was verified by immunoflourescence staining of brain slices from WT and MeCP2 A140V male mice. The staining was performed with a C-terminal MeCP2 antibody to demonstrate that the MeCP2 protein was not truncated by the A140V mutation.
The initial characterization of the MeCP2 A140V mouse has revealed some interesting abnormalities. During casual observation the mice appear normal with no variation in weight or body morphology and no indications of seizures or tremors. However, there are cellular abnormalities in the brain consistent with those seen in RTT syndrome and other diseases resulting in mental retardation. An increase in cell packing density was apparent upon histological studies of brain tissue from the mutant animals. Qualitative differences in cell density in the cerebellum were confirmed by performing cell counts. The results of these cell counts showed statistically significant differences in cell density. Increased cell packing density has been previously noted in both human RTT patients  and in RTT mouse models [39, 44, 45]. The MeCP2 null mouse created by deletion of exon 3 revealed increases in cell density in the hippocampus, cerebral cortex, and cerebellum that closely parallel our own results . A study of the brains of three RTT patients found an increase in cell-packing density in multiple brain regions including the cerebral cortex, basal ganglia, thalamus, hippocampus, and amygdala. Abnormalities were also reported in the cerebellum although an increase in cell packing density was not reported .
We find no previous descriptions of cell density abnormalities in the olfactory bulbs of Rett mouse models. We are uncertain if this is because cell density abnormalities have not previously been seen in olfactory bulbs or if the olfactory bulbs were not examined in these mice. There have been reports of defects in neuronal development in olfactory neurons from the nasal epithelium of RTT patients . In addition, defects of olfactory neuron maturation and protein expression have been found in two previously described RTT mouse models [48–51], indicating that olfactory defects are not unusual in RTT or in RTT mouse models. In addition, a recent and very thorough study of brain morphology found changes in the volume and shape of olfactory bulbs in two MeCP2 null mouse models . We have seen abnormalities in the shape of olfactory bulbs and the morphology of glomeruli in some the A140V male hemizygous mice although this has not been quantified and will be the subject of further study.
A lack of branching complexity in cortical pyramidal neurons in many brain regions has been reported in human cases of RTT [6–9] as well as in mouse models [44, 45]. In fact, dendritic branching anomalies are often found in conjunction with mental retardation of many causes [52, 53]. The A140V mutation is strongly associated with mental retardation [23–26]; therefore, we felt that abnormal dendritic branching patterns of neurons would likely occur in this new mouse model. We explored the branching complexity of neurons in the A140V mouse model and found differences between WT and MeCP2 A140V mice. We noted significant differences in the branching complexity of both the apical and basal dendrites of layer II/III pyramidal neurons of the somatosensory cortex as measured by Scholl analysis. This correlates closely with other reports of decreases in branching complexity of cortical pyramidal neurons in tissue from both human RTT patients and in Mecp2 mutant mouse models. We also found apparent differences in branching complexity in the visual cortex although this has not yet been quantified.
The MeCP2 A140V mouse has proven to be distinct from other mouse models of MeCP2 mutation. Like its human counterpart, the A140V mutation in mice produces symptoms both correlating with and disparate from the classical symptoms of RTT. In humans, the A140V mutation causes a mental retardation syndrome that has associated with it abnormalities of gait, kyphoscoliosis, mild microcephaly, spasticity, dysarthric speech, and occasionally mental illness such as schizophrenia [21, 23, 26, 27]. However certain features of classic Rett syndrome such as stereotypic hand movements, breathing abnormalities and seizures [2, 3] are notably absent in humans with the A140V mutation. These distinctions suggest that the A140V mutation affects certain functions of the MeCP2 protein while preserving others. There is for instance the report indicating that the MeCP2 A140V protein has an increased binding affinity for unmethylated DNA , the functional consequences of which are unknown. There is also the interesting finding that although the A140V mutation preserves the methyl-CpG binding function of MeCP2 it does interfere with binding to the mental retardation associated protein ATRX . This raises the possibility that disruption of the MeCP2-ATRX interaction is in someway related to the neurological symptoms that occur in both humans with the A140V mutation and in our engineered mice.
ATRX is chromatin remodeling protein that is a SWI2/SNF2 DNA helicase ATPase that is the cause of ATRX syndrome . This protein has only recently been identified as a binding partner of the MeCP2 protein. Analysis of brain tissue from MeCP2-null mice revealed that loss of MeCP2 in mature neurons leads to delocalization of the ATRX protein, suggesting that MeCP2 may be required for the proper localization of ATRX. In vitro studies done using fusion proteins in mouse fibroblasts revealed that the MeCP2 A140V protein, while properly localized to heterochromatin within the nucleus, fails to recruit ATRX to the heterochromatin. In contrast, WT MeCP2 protein efficiently recruits ATRX to heterochromatin . This failure to localize ATRX to heterochromatin may be important in understanding the normal function of both the MeCP2 and ATRX proteins.
We believe that it is important to note that the mice used in these experiments belong to early generations (F1 to F4) and are therefore in a mixed 129X1/S1 and C57BL/6 background. In addition, the neomycin resistance gene cassette used in the construction of these mice has not been excised from the experimental animals although we have begun production of a line of mice in which the neo cassette has been removed. As genetic background and the presence of extra DNA sequences such as the neo cassette can contribute to phenotype we will be repeating these experiments in later generation mice lacking the neo cassette in order to confirm our experimental results. However, we believe that, given the close parallels of our data with that seen in other mouse models of Mecp2 gene disruption, the phenotype we have observed is in fact due to the A140V mutation itself.
We believe that this new mouse model will provide insight into the functions of MeCP2, including its association with the ATRX protein. The A140V mouse has proven to reproduce some of the abnormalities of other Mecp2 mouse models (increased cell packing density and decreased neuronal dendritic arbors) while failing to reproduce others (seizures, tremors, kyphosis, breathing abnormalities, shortened life span). With this knowledge we can continue dissecting the functions of MeCP2 in the hopes of explaining its relationship to mental retardation and other clinical symptoms.
Generation of A140V "knock-in" mice
Breeding protocols and all animal experiments were approved by the Institutional Animal Care and Use Committee (IACUC) of St. Joseph's Hospital and Medical Center. An 11 kbp Bam HI fragment of the mouse MeCP2 gene, that included exon 3 and part of exon 4, was isolated by restriction digestion of a BAC clone (mBAC B22804). The 5'- end of the insert was first trimmed by restriction digestion with Pml I. A pGK-Neo cassette (flanked by two Frt sites and a single LoxP site, gift of Dr. Dymecki (Department of Genetics, Harvard Medical School), was inserted into the Nde I site located about 1.7 kbp upstream of exon 3. A second LoxP site and a novel Acl I restriction were inserted into the 3'-UTR of exon 4 (into an Mfe I site located about 400 bp downstream of the translation termination codon). A single base mutation was introduced using the QuikChangeXL kit (Stratagene Inc., Cedar Creek, Texas): a C to T change at nucleotide position 601 of the Mecp2-e2 mRNA, resulting in the A140V missense mutation. Pml I linearized targeting vector was electroporated into the R1 line of ES cells  (male genotype, Strain 129X1/S1) under previously described conditions . G418 (neomycin analogue) resistant clones were tested for proper recombination at the 3'-integration site by a PCR based assay using the following primers:
F30: 5' CGACAAGCACAGTCAGGTTGAAGAC 3'
B34: 5' TCCCAAGAGTCCCATAGTTTCTCC 3'
The wild-type allele yields an amplimer that is 322 bp long, while the mutant allele yields an amplimer that is 362 bp long. Random integration of the targeting vector into the mouse genome results in both wild-type and mutant bands. The PCR product was also digested with Acl I, which cuts the mutant amplimer into two segments (227 bp and 135 bp), leaving the wild-type amplimer uncut. Selected ES clone DNAs were tested by Southern blot for correct recombination at the 5'end, using Probe A. Homologous recombination at the 5' end results in a 5.5 kbp band, and clones that retain the wild-type locus produce an 11 kbp band. Finally, selected positive ES cell clones were verified by sequencing to confirm the presence of the desired point mutation. Two ES cell clones (169J6 and 177U9) were then injected into blastocysts from C57BL/6 mice (done under contract by Ingenious Targeting Laboratories, Inc., Stony Brook, New York) and implanted into pseudo-pregnant females. Male chimeras were harem bred with wild-type C57BL/6 mice and tail DNAs from all female F1 pups were tested for the presence of the transgene. Founder females (derived from ES clone 177U9) were identified by PCR, Southern blot, and DNA sequencing. These founder females were used to establish our colony of A140V mice by backcrossing with WT C57BL/6NCrL male mice (Charles River, Wilmington, Massachusetts), yielding mutant hemizygous males, heterozygous females, and WT controls. Heterozygous females produced in the colony were backcrossed with WT C57BL/6NCrL male mice to produce experimental mice as well as additional breeding stock.
Total RNA was extracted from the cerebella of 2 mutant and 2 WT male mice and treated with DNase I to remove traces of genomic DNA. cDNA was synthesized using random hexamers (Superscript III kit, Invitrogen, Inc., Carlsbad, California). cDNA from each of these four animals was used in PCR reactions with the F30 and B34 primers described above. The amplimer from mutant animals is 40 bp larger than the amplimer from WT animals. A second cDNA fragment (729 bp) that included a portion of exon 3 and exon 4, containing the A140V point mutation was then amplified using the following primers:
U256 (located within exon 3): 5' GTATGATGACCCCACCTTGC 3'
L1452 (located within exon 4): 5' TTCAGTCCCTTCCCGCTTTT 3'
The cDNA amplimers from WT and mutant RNAs were gel purified and sequenced to verify WT or mutant status at the codon for amino acid 140. When genomic DNA was used as a template for PCR using these same primers, the amplimer was 1216 bp long (providing a control for contamination of the RNA by genomic DNA).
Total RNA was extracted from cerebella of three mutant male mice and three WT male littermates (6 months old) using Trizol (Invitrogen, Inc., Carlsbad, California) and cleaned up using an RNA extraction kit (SA Biosciences, Frederick, MD). First strand cDNA was synthesized (kit from SA Biosciences) and used in qRT-PCR reactions using PCR assays and SYBR Green master mix from SA Biosciences (Mecp2, cat no. PPM31215E, and Gapdh, cat no. PPM02946E). Controls were first done with mouse reference RNA to verify comparable efficiency of PCR reactions, and negative controls included no-reverse transcriptase (NRT) reactions for each RNA. Triplicate reactions were done for each primer assay and each of the 6 cDNA samples. Threshold level of fluorescence was set across the entire run within the exponential phase of amplification. The corresponding Ct values were then determined for each sample in the run. The means, standard deviations, and p value were calculated using GraphPad InStat3 software.
Histology: Cresyl Violet Staining of Brain Tissue
Mice were anesthetized and transcardially perfused with saline followed by 4% buffered paraformaldehyde (PFA). The brains were then post-fixed in 4% PFA overnight at 4°C and then cryoprotected in 30% sucrose for 1-2 days. Subsequently, brains were frozen in an isopentane/dry ice bath. The brains were immediately sectioned into 30 μm slices using a cryostat, slices were placed on slides, and then kept frozen at -20°C until staining. Alternating brain slices were then thawed briefly and stained with cresyl violet (Sigma, St. Louis, Missouri), cover slipped with Permount (Fisher Scientific, Pittsburgh, PA) and were visualized with either an Olympus microscope or a Zeiss AxioImager microscope (for brightfield Z-stack images).
Cell Nuclei Count Analysis
Cell nuclei counts were performed in the cerebellum (using brightfield z-stack microscopy) in order to quantify differences in cell nuclei number. This was done using brightfield Z-stack images of the granule cell layer of the cerebellum in cresyl violet stained tissue. A rectangular counting area was drawn on the Z-stack images using Axiovision software. This demarcated area carried through the entire Z-stack. Calculating the distance between the top and bottom slices of the stack in conjunction with the demarcated area allowed for a volume measurement to be made. All cell nuclei counts were done in a total volume of 80 mm3. Using this counting method, nuclei were clear and easily distinguishable from each other. Triplicate cell counts were performed in each region of the cerebellar granule cell layer from WT and MeCP2 A140V mice. The mean, standard deviation and p values were calculated using GraphPad InStat3 software.
Histology: Golgi-Cox Staining of Brain Tissue
The Rapid Golgi-Cox staining kit (FD Neurotechnologies, Ellicott City, Maryland) was used for staining whole mouse brains. Mice were euthanized by overdose of isofluorane and the brains removed. After rinsing in de-ionized water the brains were incubated for 2 weeks in a Solution A/B mixture (impregnation) following the manufacturer's protocol. The brains were then moved to Solution C (cryoprotection) for 4-5 days and subsequently frozen in an isopentane/dry ice bath. The brains were immediately sectioned into 100-200 μm slices using a cryostat and the slices were mounted on gelatin-coated slides. After being allowed to dry for 3-5 days, the staining protocol for development of the black precipitate was completed using kit reagents. The tissue was counterstained with cresyl violet (Sigma, St. Louis, Missouri). Cover slips were mounted using Permount (Fisher Scientific, Pittsburgh, Pennsylvania) and slides were visualized using a Zeiss AxioImager microscope capable of brightfield Z-stack.
Scholl analysis  was adapted for use on brightfield Z-stack images using Axiovision software. Concentric circles (Scholl lines) were drawn at 20 μm increments from the center of the cell body. The Scholl lines were superimposed on the entire stack of images allowing the analysis to be conducted in a 3-dimensional fashion. The dendritic arbor was followed through the Z-stack and the number of intersections made by dendrites with the Scholl lines was measured as each dendrite traveled away from the cell body. The Z-stack image slices were separated by a depth of only 0.280 μm preventing intersections from being missed.
The apical and basal arbors of 10 neurons from a MeCP2 A140V mouse and 10 neurons from a WT mouse were captured in Z-stack images. All neurons were layer II/III pyramidal neurons of similar morphology, located in the somatosensory cortex at similar coordinates . Scholl lines were placed on the images every 20 μm until no more dendrites crossed the Scholl lines. Axiovision software was then used to manually mark crossings of each Scholl line by the dendrites of the neurons. Crossings at each Scholl line were summed and the mean and standard deviation calculated. p values comparing the wild type and A140V mouse neurons at each Scholl line were then determined. GraphPad InStat3 software was used for statistical analysis.
Brain tissue from WT and A140V mutant mice was frozen in an isopentane/dry ice bath and 10 μm frozen sections were cut on a cryostat, placed on slides, and frozen at -20°C until staining. Tissue was then fixed with 4% PFA, blocked and permeabilized with a mixture of 10% goat serum, 1% BSA, and 0.2% Triton X100, and incubated overnight at 4°C with anti-MeCP2 antibody (PA1-888 rabbit anti-MeCP2 antibody, Affinity BioReagents, Rockford, Illinois). This is a polyclonal antibody that recognizes the C-terminus of the MeCP2 protein. Sections were then incubated with secondary antibody (Alexa Fluor 488 goat anti-rabbit antibody, Invitrogen, Carlsbad, California) for 2 hours at room temperature. Following a wash step, sections were coverslipped with Pro-long Gold (Invitrogen, Carlsbad, California) mounting medium. MeCP2 staining in the slices was visualized using a Zeiss confocal microscope.
This work was supported by funds from the NIH (to SN; P01-HD024448) and the Barrow Neurological Foundation (to VN). The authors would like to thank Ed Mallick for expert technical assistance with gene targeting in ES cells.
- Amir RE, Veyver Van Den IB, Wan M, Tran CQ, Franke U, Zoghbi HY: Rett syndrome is caused by mutations in X-linked MECP2, encoding methyl-CpG-binding protein 2. Nature Genetics. 1999, 23: 185-188. 10.1038/13810.View ArticlePubMedGoogle Scholar
- Hagberg B, Aicardi J, Dias K, Ramos O: A progressive syndrome of autism, dementia, ataxia, and loss of purposeful hand use in girls: Rett's syndrome: report of 35 cases. Annals of Neurology. 1983, 14: 471-479. 10.1002/ana.410140412.View ArticlePubMedGoogle Scholar
- Hagberg B: Rett's Syndrome: Prevalence and Impact on Progressive Severe Mental Retardation in Girls. Acta Paediatrica Scandinavica. 1985, 74: 405-408. 10.1111/j.1651-2227.1985.tb10993.x.View ArticlePubMedGoogle Scholar
- Dunn HG, MacLeod PM: Rett syndrome: review of biological abnormalities. Can J Neurol Sci. 2001, 28: 16-29.PubMedGoogle Scholar
- Bauman ML, Kemper TL, Arin DM: Pervasive neuroanatomic abnormalities of the brain in three cases of Rett's syndrome. Neurology. 1995, 45: 1581-1586.View ArticlePubMedGoogle Scholar
- Belichenko PV: Rett syndrome: 3-D confocal microscopy of cortical pyramidal dendrites and afferents. NeuroReport. 1994, 5: 1509-1513. 10.1097/00001756-199407000-00025.View ArticlePubMedGoogle Scholar
- Armstrong D, Dunn JK, Antalffy B, Trivedi R: Selective dendritic alterations in the cortex of Rett syndrome. Journal of Neuropathology and Experimental Neurology. 1995, 54: 195-201. 10.1097/00005072-199503000-00006.View ArticlePubMedGoogle Scholar
- Armstrong DD: Neuropathology of Rett syndrome. J Child Neurol. 2005, 20: 747-753. 10.1177/08830738050200082401.View ArticlePubMedGoogle Scholar
- Armstrong DD, Dunn K, Antalffy B: Decreased dendritic branching in frontal, motor and limbic cortex in Rett syndrome compared with trisomy 21. J Neuropathol Exp Neurol. 1998, 57: 1013-1017. 10.1097/00005072-199811000-00003.View ArticlePubMedGoogle Scholar
- Neul JL, Zoghbi HY: Rett syndrome: a prototypical neurodevelopmental disorder. Neuroscientist. 2004, 10: 118-128. 10.1177/1073858403260995.View ArticlePubMedGoogle Scholar
- Nan X, Campoy FJ, Bird A: MeCP2 is a transcriptional repressor with abundant binding sites in genomic chromatin. Cell. 1997, 88: 471-481. 10.1016/S0092-8674(00)81887-5.View ArticlePubMedGoogle Scholar
- Nan X, Tate P, Li E, Bird A: DNA methylation specifies chromosomal localization of MeCP2. Mol Cell Biol. 1996, 16: 414-421.PubMed CentralView ArticlePubMedGoogle Scholar
- Chahrour M, Jung SY, Shaw C, Zhou X, Wong ST, Qin J, Zoghbi HY: MeCP2, a key contributor to neurological disease, activates and represses transcription. Science. 2008, 320: 1224-1229. 10.1126/science.1153252.PubMed CentralView ArticlePubMedGoogle Scholar
- Jones PL, Veenstra GJ, Wade PA, Vermaak D, Kass SU, Landsberger N, Strouboulis J, Wolffe AP: Methylated DNA and MeCP2 recruit histone deacetylase to repress transcription. Nat Genet. 1998, 19: 187-191. 10.1038/561.View ArticlePubMedGoogle Scholar
- Sun YE, Wu H: The ups and downs of BDNF in Rett syndrome. Neuron. 2006, 49: 321-323. 10.1016/j.neuron.2006.01.014.View ArticlePubMedGoogle Scholar
- Zhou Z, Hong EJ, Cohen S, Zhao W, Ho HH, Schmidt L, Chen WG, Lin Y, Savner E, Griffith EC, et al.: Brain-specific phosphorylation of MeCP2 regulates activity-dependent Bdnf transcription, dendritic growth, and spine maturation. Neuron. 2006, 52: 255-269. 10.1016/j.neuron.2006.09.037.PubMed CentralView ArticlePubMedGoogle Scholar
- Poo MM: Neurotrophins as synaptic modulators. Nat Rev Neurosci. 2001, 2: 24-32. 10.1038/35049004.View ArticlePubMedGoogle Scholar
- Chang Q, Khare G, Dani V, Nelson S, Jaenisch R: The disease progression of Mecp2 mutant mice is affected by the level of BDNF expression. Neuron. 2006, 49: 341-348. 10.1016/j.neuron.2005.12.027.View ArticlePubMedGoogle Scholar
- Meloni I, Bruttini M, Longo I, Mari F, Rizzolio F, D'Adamo P, Denvriendt K, Fryns JP, Toniolo D, Renieri A: A mutation in the rett syndrome gene, MECP2, causes X-linked mental retardation and progressive spasticity in males. Am J Hum Genet. 2000, 67: 982-985. 10.1086/303078.PubMed CentralView ArticlePubMedGoogle Scholar
- Imessaoudene B, Bonnefont JP, Royer G, Cormier-Daire V, Lyonnet S, Lyon G, Munnich A, Amiel J: MECP2 mutation in non-fatal, non-progressive encephalopathy in a male. J Med Genet. 2001, 38: 171-174. 10.1136/jmg.38.3.171.PubMed CentralView ArticlePubMedGoogle Scholar
- Couvert P, Bienvenu T, Aquaviva C, Poirier K, Moraine C, Gendrot C, Verloes A, Andres C, Le Fevre AC, Souville I, et al.: MECP2 is highly mutated in X-linked mental retardation. Hum Mol Genet. 2001, 10: 941-946. 10.1093/hmg/10.9.941.View ArticlePubMedGoogle Scholar
- Bienvenu T, Chelly J: Molecular genetics of Rett syndrome: when DNA methylation goes unrecognized. Nature Reviews: Genetics. 2006, 7: 415-426. 10.1038/nrg1878.View ArticlePubMedGoogle Scholar
- Dotti MT, Orrico A, De Stephano N, Battisti C, Sicurelli F, Severi S, Lam CW, Galli L, Sorrentino V, Federico A: A Rett syndrome MECP2 mutation that causes mental retardation in men. Neurology. 2002, 58: 226-230.View ArticlePubMedGoogle Scholar
- Klauck SM, Lindsay S, Beyer KS, Splitt M, Burn J, Poustka A: A mutation hot spot for nonspecific X-linked mental retardation in the MECP2 gene causes the PPM-X syndrome. American Journal of Medical Genetics. 2002, 70: 1034-1037.Google Scholar
- Orrico A, Lam C, Galli L, Dotti MT, Hayek G, Tong SF, Poon PM, Zappella M, Federico A, Sorrentino V: MECP2 mutation in male patients with non-specific X-linked mental retardation. FEBS Lett. 2000, 481: 285-288. 10.1016/S0014-5793(00)01994-3.View ArticlePubMedGoogle Scholar
- Winnepenninckx B, Errijgers V, Hayez-Delatte F, Reyniers E, Kooy RF: Identification of a family with nonspecific mental retardation (MRX79) with the A140V mutation in the MECP2 gene: Is there a need for routine screening?. Human Mutation. 2002, 20: 249-252. 10.1002/humu.10130.View ArticlePubMedGoogle Scholar
- Cohen D, Lazar G, Couvert P, Desportes V, Lippe D, Mazet P, Heron D: MECP2 mutation in a boy with language disorder and schizophrenia. Am J Psychiatry. 2002, 159: 148-149. 10.1176/appi.ajp.159.1.148-a.View ArticlePubMedGoogle Scholar
- Ohki I, Shimotake N, Fujita N, Jee J, Ikegami T, Nakao M, Shirakawa M: Solution structure of the methyl-CpG binding domain of human MBD1 in complex with methylated DNA. Cell. 2001, 105: 487-497. 10.1016/S0092-8674(01)00324-5.View ArticlePubMedGoogle Scholar
- Nan X, Hou J, Maclean A, Nasir J, Lafuente MJ, Shu X, Kriaucionis S, Bird A: Interaction between chromatin proteins MECP2 and ATRX is disrupted by mutations that cause inherited mental retardation. Proceedings of the National Academy of Sciences USA. 2007, 104: 2709-2714. 10.1073/pnas.0608056104.View ArticleGoogle Scholar
- Kudo S, Nomura Y, Segawa M, Fujita N, Nakao M, Hammer S, Schanen C, Terai I, Tamura M: Functional characterisation of MeCP2 mutations found in male patients with X linked mental retardation. J Med Genet. 2002, 39: 132-136. 10.1136/jmg.39.2.132.PubMed CentralView ArticlePubMedGoogle Scholar
- Stevenson RE: Alpha-Thalassemia X-Linked Mental Retardation Syndrome. GeneReviews. 2009, [http://0-www.ncbi.nlm.nih.gov.brum.beds.ac.uk/bookshelf/br.fcgi?book=gene&part=xlmr]Google Scholar
- Villard L, Fontes M: Alpha-thalassemia/mental retardation syndrome, X-linked (ATR-X, MIM #301040, ATR-X/XNP/XH2 gene MIM #300032. European Journal of Human Genetics. 2002, 10: 223-225. 10.1038/sj.ejhg.5200800.View ArticlePubMedGoogle Scholar
- Gibbons RJ, Higgs DR: Molecular-clinical spectrum of the ATR-X syndrome. American Journal of Medical Genetics. 2000, 97: 204-212. 10.1002/1096-8628(200023)97:3<204::AID-AJMG1038>3.0.CO;2-X.View ArticlePubMedGoogle Scholar
- Badens C, Lacoste C, Philip N, Martini N, Courrier S, Giuliano F, Verloes A, Munnich A, Leheup B, Burglen L, et al.: Mutations in PHD-like domain of the ATRX gene correlate with severe psychomotor impairment and severe urogenital abnormalities in patients with ATRX syndrome. Clinical Genetics. 2006, 70: 57-62. 10.1111/j.1399-0004.2006.00641.x.View ArticlePubMedGoogle Scholar
- Garrick D, Sharpe JA, Arkell R, Dobbie L, Smith AJ, Wood WG, Higgs DR, Gibbons RJ: Loss of Atrx affects trophoblast development and the pattern of X-inactivation in extraembryonic tissues. PLoS Genet. 2006, 2: e58-10.1371/journal.pgen.0020058.PubMed CentralView ArticlePubMedGoogle Scholar
- Berube NG, Mangelsdorf M, Jagla M, Vanderluit J, Garrick D, Gibbons RJ, Higgs DR, Slack RS, Picketts DJ: The chromatin-remodeling protein ATRX is critical for neuronal survival during corticogenesis. J Clin Invest. 2005, 115: 258-267.PubMed CentralView ArticlePubMedGoogle Scholar
- Medina CF, Mazerolle C, Wang Y, Berube NG, Coupland S, Gibbons RJ, Wallace VA, Picketts DJ: Altered visual function and interneuron survival in Atrx knockout mice: inference for the human syndrome. Hum Mol Genet. 2009, 18: 966-977. 10.1093/hmg/ddp034.View ArticlePubMedGoogle Scholar
- Guy J, Hendrich B, Holmes M, Martin JE, Bird A: A mouse Mecp2 -null mutation causes neurolgical symptoms that mimic Rett syndrome. Nature Genetics. 2001, 27: 322-326. 10.1038/85899.View ArticlePubMedGoogle Scholar
- Chen RZ, Akbarian S, Tudor M, Jaenisch R: Deficiency of methyl-CpG binding protein-2 in CNS neurons results in a Rett-like phenotype in mice. Nature Genetics. 2001, 27: 327-331. 10.1038/85906.View ArticlePubMedGoogle Scholar
- Shahbazian MD, Young JI, Yuva-Paylor LA, Spencer CM, Antalffy BA, Noebels JL, Armstrong DL, Paylor R, Zoghbi HY: Mice with truncated MeCP2 recapitulate many Rett syndrome features and display hyperacetylation of histone H3. Neuron. 2002, 35: 243-254. 10.1016/S0896-6273(02)00768-7.View ArticlePubMedGoogle Scholar
- McGill BE, Bundle SF, Yaylaoglu MB, Carson JP, Thaller C, Zoghbi HY: Enhanced anxiety and stress-induced corticosterone release are associated with increased Crh expression in a mouse model of Rett syndrome. Proc Natl Acad Sci USA. 2006, 103: 18267-18272. 10.1073/pnas.0608702103.PubMed CentralView ArticlePubMedGoogle Scholar
- Lawson-Yuen A, Liu D, Han L, Jiang ZI, Tsai GE, Basu AC, Picker J, Feng J, Coyle JT: Ube3a mRNA and protein expression are not decreased in Mecp2R168X mutant mice. Brain Research. 2007, 1180: 1-6. 10.1016/j.brainres.2007.08.039.PubMed CentralView ArticlePubMedGoogle Scholar
- Belichenko NP, Belichenko PV, Li HH, Mobley WC, Francke U: Comparative study of brain morphology in Mecp2 mutant mouse models of Rett syndrome. J Comp Neurol. 2008, 508: 184-195. 10.1002/cne.21673.View ArticlePubMedGoogle Scholar
- Fukuda T, Itoh M, Ichikawa T, Washiyama K, Goto Y: Delayed maturation of neuronal architecture and synaptogenesis in cerebral cortex of Mecp2-deficient mice. J Neuropathol Exp Neurol. 2005, 64: 537-544.PubMedGoogle Scholar
- Kishi N, Macklis JD: MECP2 is progressively expressed in post-migratory neurons and is involved in neuronal maturation rather than cell fate decisions. Mol Cell Neurosci. 2004, 27: 306-321.View ArticlePubMedGoogle Scholar
- Scholl DA: Dendritic organization in the neurons of the visual and motor cortices of the cat. Journal of Anatomy. 1953, 87: 387-406.Google Scholar
- Ronnett GV, Leopold D, Cai X, Hoffbuhr KC, Moses L, Hoffman EP, Naidu S: Olfactory biopsies demonstrate a defect in neuronal development in Rett's syndrome. Ann Neurol. 2003, 54: 206-218. 10.1002/ana.10633.View ArticlePubMedGoogle Scholar
- Degano AL, Pasterkamp RJ, Ronnett GV: MeCP2 deficiency disrupts axonal guidance, fasciculation, and targeting by altering Semaphorin 3F function. Mol Cell Neurosci. 2009, 42: 243-254. 10.1016/j.mcn.2009.07.009.PubMed CentralView ArticlePubMedGoogle Scholar
- Matarazzo V, Cohen D, Palmer AM, Simpson PJ, Khokhar B, Pan SJ, Ronnett GV: The transcriptional repressor Mecp2 regulates terminal neuronal differentiation. Mol Cell Neurosci. 2004, 27: 44-58. 10.1016/j.mcn.2004.05.005.View ArticlePubMedGoogle Scholar
- Matarazzo V, Ronnett GV: Temporal and regional differences in the olfactory proteome as a consequence of MeCP2 deficiency. Proc Natl Acad Sci USA. 2004, 101: 7763-7768. 10.1073/pnas.0307083101.PubMed CentralView ArticlePubMedGoogle Scholar
- Palmer A, Qayumi J, Ronnett G: MeCP2 mutation causes distinguishable phases of acute and chronic defects in synaptogenesis and maintenance, respectively. Molecular and Cellular Neuroscience. 2008, 37: 794-807. 10.1016/j.mcn.2008.01.005.View ArticlePubMedGoogle Scholar
- Machado-Salas JP: Abnormal dendritic patterns and aberrant spine development in Bourneville's disease--a Golgi survey. Clin Neuropathol. 1984, 3: 52-58.PubMedGoogle Scholar
- Kaufmann WE, Moser HW: Dendritic anomalies in disorders associated with mental retardation. Cerebral Cortex. 2000, 10: 981-991. 10.1093/cercor/10.10.981.View ArticlePubMedGoogle Scholar
- Nagy A, Rossant J, Nagy R, Abramow-Newerly W, Roder JC: Derivation of completely cell culture-derived mice from early-passage embryonic stem cells. Proc Natl Acad Sci USA. 1993, 90: 8424-8428. 10.1073/pnas.90.18.8424.PubMed CentralView ArticlePubMedGoogle Scholar
- Homanics GE, Ferguson C, Quinlan JJ, Daggett J, Snyder K, Lagenaur C, Mi ZP, Wang XH, Grayson DR, Firestone LL: Gene knockout of the alpha6 subunit of the gamma-aminobutyric acid type A receptor: lack of effect on responses to ethanol, pentobarbital, and general anesthetics. Mol Pharmacol. 1997, 51: 588-596.PubMedGoogle Scholar
- Paxinos G, Franklin K: The Mouse Brain in Stereotaxic Coordinates. 2001, San Diego, CA 92101 USA: Academic Press, 2Google Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.